277 results about "Nucleic Acid Vaccines" patented technology

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

The present invention discloses one medicinal polymer (PELGE/PELGA) nanometer particle carrier and its preparation process and use. The carrier material is PELGE material of different molecular weights, different LA/GA ratios and different PEG contents, and the nanometer PELGE/PELGA carrier particle is prepared through evaporation process. The said copolymer is self-assembled in water into nanometer particle or micelle, and its hydrophobic PLGA segment coagulates into the core while the hydrophilic polyglycol forms hydrophilic shell. The carrier may be used for the nanometer preparation of plasmid, nucleic acid vaccine, antisense oligodeoxynucleotide or ribozyme for genetic treatment; the nanometer preparation of various chemical medicines; and the nanometer preparation of polypeptide and protein medicines.

The invention belongs to the technical field of biological medicine, relating to an HIV-1gp120 gene consensus sequence optimized by codons and a gp120 nucleic acid vaccine. In the invention, a Chinese HIV-1 epidemic strain (A/E recombinant subtype, B/C recombinant subtype and ThB subtype) envelope protein gp120 consensus amino acid sequence is obtained by applying multi-sequence comparative analysis; a gp120 gene segment encoding the consensus amino acid sequence is prepared by using an artificially synthesized method, and the gene is optimized by the codons and combines preferences of mammalian cells and escherichia coli codons; and on the basis, HIV-1gp120 nucleic acid vaccine consisting of the gp120 gene and eukaryotic expression vector pJW4303 is constructed. The nucleic acid vaccine can be applied to animal and human immunization and expression and production of the gp120 protein.

The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection.

The invention discloses gene orders of schistosoma japonicum recombinant multi-epitope antigens BSjGCP-BSj23 and BSjGCP-BSj23-BSj28, a method for expressing and purifying the same, and application thereof in preparing schistosomiasis japonica immunity prevention vaccines and diagnostic reagents. Recombinant multi-epitope nucleic acid vaccines pCMV-BSjGCP-BSj23 and pCMV-BSjGCP-BSj23-BSj28 obtain 14.76 percent and 64.95 percent of worm reduction rates respectively in Kunming mice. The recombinant multi-epitope antigens pGEX-BSjGCP-BSj23 and pGEX-BSjGCP-BSj23-BSj28 obtain 15.7 percent and 57.99 percent of worm reduction rates in immunizing BalB/c mice, and obtain 91.0 percent and 89.9 percent of sensitivities as well as 97.8 percent and 93.4 percent of specificities respectively as diagnostic antigens.

The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus antigen comprising sequence from more than one flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.

A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

The invention relates to a condon optimized African swine fever virus P54 gene and a nucleic acid vaccine based on the gene, wherein the nucleic acid vaccine consists of an eukaryotic expression vector and the condon optimized African swine fever virus P54 gene. The nucleic acid vaccine is constructed through the following steps of optimizing the condon of P54protein, designing a specific primer, transferring sequence of the artificially synthesized African swine fever virus P54 gene into a cloning vector and recombining the purified P54 gene into the eukaryotic expression vector. The nucleic acid vaccine can be used for preventing the occurrence of African swine fever and is a powerful tool for solving the immune prevention and control of the African swine fever. Compared with the traditional vaccines, the nucleic acid vaccine has the advantages of small quantity, security, long-term effect, stability and convenience in operation when reaching same immune effect.

The present invention relates to biomedicine engineering technology, and is the gene cloning of polyepitope antigen of hepatitis C virus hcvme and the coded polyepitope antigen HCVME. The hcvme includes 9 epitope genes of HVR1 simulating B cell and 4 epitope genes of T cell in E2 region of HCV genome, and the 4 epitope genes of T cell includes 2 of conservative CTL epitope in region C, 1 of conservative CTL epitope in region NS3 and 1 of conservative Th epitope in region NS3. Serial tests show that hcvme has high cross reaction with karyogamy expressed product GST-HCVME of gst gene and positive hepatitis C antibody serum, and the GST-HCVME immunized male rabbit serum has high distinction frequency on natural HVR1 synthetic peptide. Therefore, hcvme and its expressing product HCVME may be used in preparing nucleic acid vaccine and polypeptide vaccine for hepatitis C and the test reagent for HCV antigen and antibody.

The invention discloses a grass carp reovirus S11 gene eukaryotic expression recombinant plasmid preparation method and application thereof in serving as nucleic acid vaccine, and belongs to the technical field of gene engineering and molecular immunology. The preparation method disclosed by the invention is characterized by comprising the steps of extracting viral genome RNA, performing reverse transcription to convert the viral genome RNA into cDNA, amplifying a corresponding DNA sequence out, constructing the DNA sequence to pcDNA-3.1(+) plasmid, converting Escherichia coli DH5alpha, screening out positive clone bacteria containing recombinant plasmid, culturing a lot of the positive bacteria and extracting recombinant plasmid S11-pcDNA3.1 contained in the bacteria. The recombinant plasmid is utilized as nucleic acid vaccine to perform intramuscular injection on the grass carps, and the nucleic acid vaccine enters the muscle cells and expresses VP35 protein of the grass carp reovirus in the muscle cells; thus, fish body immune cell proliferation is stimulated, antiviral related gene expression is up regulated, fish bodies are stimulated to generate antiviral antibodies, and capability of grass carps in resisting grass carp reovirus infection is effectively improved; furthermore, the grass carp reovirus S11 gene eukaryotic expression recombinant plasmid can be used for preventing a grass carp hemorragic disease caused by the grass carp reovirus in aquaculture.

The invention relates to a hepatitis B virus nucleic acid vaccine optimized by codon. In the invention, hepatitis B surface antigen (HBs) gene order (adr subtype) is analyzed to find codon locus which tells the differences between the codon preferences of the gene order and the codon preferences of the mammal; the codon of the HBs gene order is replaced to obtain the surface antigen gene; the gene order is combined and expanded to obtain MHBs, Pst I, BamH I, double digestion MHBs gene and carrier pSW3891 plasmid optimized by the codon; 10ul connection system is configured to obtain a middle protein gene. The nucleic acid vaccine of the invention overcomes the defects that the differences between prokaryote and eukaryote in terms of codon preferences cause that the foreign gene can not be expressed effectively in mammal reservoir and can not generate relatively good immune sheltering effect; in addition, the invention remarkably improve protein expression of the foreign gene in the mammal reservoir, effectively stimulates immune system of the reservoir to generate relatively good immunological reaction of human body fluids and cellular immune response.

The invention provides a method for preparing a chicken genetic engineering immunopotentiator by an akirin2 gene sequence, relating to a method for preparing a chicken genetic engineering immunopotentiator. The invention solves the problem that the existing genetic engineering immunoenhancement nucleic acid vaccines can not extensively improve the immunity effects of vaccines and bacterins. The method comprises the following steps of: acquiring a chicken akirin2 gene coded sequence; acquiring a recombinant pMD18-T vector containing the chicken akirin2 gene; designing a primer and enabling the 5'- terminals to have HindIII and EcoRI restriction sites, subcloning the chicken akirin2 gene in the recombinant pMD18-T vector into an expression vector to construct a recombinant expression vector; and diluting the recombinant expression vector by a sterile PBS (phosphate buffer solution). The chicken genetic engineering immunopotentiator provided by the invention can improve the expression levels of multiple immunity related factors such as IL-1, IL-6, toll-like receptors and the like, and has the characteristics of wide applicable range and the like for various vaccines and bacterins.

The invention provides a construction and an application of recombinant human interleukin 12 eukaryotic expression vector and relates to the development of recombinant human interleukin 12 (rhIL-12) eukaryotic expression vector, the screening of stable expression cell lines and the adjuvant function of nucleic acid vaccine gene and the therapeutical effect of tumor gene. Ten hydrophobic flexible amino acid joints are used to connect P40 and P35 to obtain fusion gene to construct rhIL-12 eukaryotic expression plasmid (pCDNA6-IL-12), then the expression plasmid is transferred to CHO cell and finally stable expression cell lines are screened. The expression product has good biological activity. Nucleic acid vaccine and pCDNA6-IL-12 are used for coimmune so as to significantly increase the immune effect. Strong antitumor effect can be exerted when the expression vector of the invention is directly injected inside the tumor of laboratory mouse tumor model or is first used to perform gene modification to tumor cells and then implanted in tumor. The expression vector of the invention can be used in the search of clinical trial stage after further perfecting.

The invention provides a preparation method of avian influenza virus HA gene recombinant adenovirus, which creatively comprises the following steps: carrying out a series of intermediate processes on plasmid pCAGGS, adenovirus shuttle plasmid pShuttle, adenovirus framework plasmid pAdEasy-1 and the like to obtain a gene expression plasmid and other intermediate products, and transfecting the obtained recombinant adenovirus plasmid with 293 cell; and carrying out immunohistochemical screening on the recombinant virus according to the adenovirus-infected cytopathy and specific cells. By using the CAG as the promoter to express the target gene, the method obviously enhances the expression level of the target gene. The hemagglutinin recombinant adenovirus for respectively expressing H5N1 and H9N2 subtype avian influenza viruses provides a virus model for development of the H5/H9 subtype avian influenza virus bivalent nucleic acid vaccine, and also lays the foundation for development of the AIV (avian influenza virus) adenovirus live vector vaccine.